By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Pharmexa A/S (formerly M&E Biotech A/S) 

6, Kogle Allé

Horsholm    DK-2970  Denmark
Phone: 45-45-16-25-25 Fax: 45-45-16-25-00



Company News
Pharmexa A/S (PHARMX.CO) and Affitech AS to Combine Operations to Create a New Antibody Therapeutics Company 3/4/2009 7:30:57 AM
Affitech AS Acquires Pharmexa A/S (PHARMX.CO)'s Diabody Technology 10/28/2008 11:31:30 AM
Pharmexa A/S (PHARMX.CO) Stops One of Two Phase III Trials 5/13/2008 6:10:13 AM
Pharmexa A/S (PHARMX.CO) Loses European Patent Appeal for Broad Claims to Telomerase-Based Cancer Vaccines 9/4/2007 11:41:45 AM
Pharmexa A/S (PHARMX.CO) and Affitech AS Enter into an Exclusive License Agreement to Promote Diabody Technology 4/3/2007 10:55:29 AM
Cobra BioManufacturing (CBF.L) Announces Manufacturing Agreement With Pharmexa 2/2/2007 1:43:20 PM
Pharmexa A/S (PHARMX.CO) Files The First Phase III Application 2/1/2006 3:03:01 PM
IDM Pharma, Inc. (IDMI) Completes Sale of Non-Core Assets To Pharmexa A/S (PHARMX.CO) For $12 Million Cash 1/3/2006 10:38:24 AM
IDM Pharma, Inc. (IDMI) Enters Agreement To Sell Non-Core Assets To Pharmexa A/S (PHARMX.CO) For $12 Million Cash 11/28/2005 10:56:56 AM
Pharmexa A/S (PHARMX.CO) To Acquire GemVax AS And Launch Rights Issue To Finance Two Large Phase III Trials In Pancreatic Cancer10/19/2005 5:13:15 PM